B-Raf kinase inhibitors for cancer treatment.
Tools
Tools
Li, Nanxin, Batt, David and Warmuth, Markus (2007) B-Raf kinase inhibitors for cancer treatment. Current opinion in investigational drugs (London, England : 2000), 8 (6). pp. 452-456. ISSN 1472-4472
Abstract
The Raf-MEK-ERK signaling pathway is critical for cell survival, growth, proliferation and tumorigenesis. Among the three isoforms of Raf protein kinases, in vitro and in vivo studies have shown that B-Raf functions as the primary MEK activator. B-Raf is one of the most frequently mutated genes in human cancers with a high prevalence in melanoma, and many of the B-Raf mutations activate the kinase activity of B-Raf. B-Raf kinase represents an excellent target for anticancer therapy based on preclinical target validation, epidemiology and drugability. Several small-molecule inhibitors of B-Raf kinase are currently undergoing clinical evaluation, with others due to enter clinical development in the near future.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | free final full text version available at publisher's official URL; author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF may be used |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:17 |
| Last Modified: | 13 Oct 2015 13:17 |
| URI: | https://oak.novartis.com/id/eprint/113 |